Street Insider reports that Inovio Pharmaceuticals Inc. (NASDAQ: INO) announced the initiation and opening of sites to enroll the second portion of the company’s Phase 3 program for VGX-3100—their DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus (HPV). Titled REVEAL 2, the company’s confirmatory stage Phase 3 clinical trial is designed to evaluate the efficacy and safety of VGX-3100. If approved, VGX-3100 would represent the first immunotherapy for women with cervical dysplasia.
What is Cervical Dysplasia?
As reported in WebMD, Cervical Dysplasia is a precancerous condition in which abnormal cell growth occurs on the surface lining of the cervix or endocervical canal, the opening between the uterus and the vagina. It is called the cervical intraepithelial neoplasia (CIN). Strongly associated with sexually transmitted human papillomavirus (HPV) infection, cervical dysplasia is most common in women under 30 but can develop at every age.
What is VGX-3100?
VGX-3100 is a therapeutic DNA vaccine being investigated for the treatment of pre-cancers and cancers such as cervical cancer, caused by the human papillomavirus (HPV) subtypes 16 and 18 (HPV-16 and HPV-18). It is being developed by Inovio Pharmaceuticals.
